NIH's Collins Supports "More Aggressive" DTC Genetic Testing Oversight
This article was originally published in The Tan Sheet
Executive Summary
National Institutes of Health Director Francis Collins, an influential supporter of genomic research and applications, says he has been urging FDA to take a "more aggressive role" in overseeing direct-to-consumer genetic tests
You may also be interested in...
FDA To Regulate Direct-To-Consumer Genetic Tests
FDA sent letters to five genetic testing firms requesting pre-market submissions for the companies' already-marketed services, citing the need to prove that direct-to-consumer genetic assays are analytically and clinically accurate
FDA To Regulate Direct-To-Consumer Genetic Tests
FDA sent letters to five genetic testing firms requesting pre-market submissions for the companies' already-marketed services, citing the need to prove that direct-to-consumer genetic assays are analytically and clinically accurate
FDA To Regulate Direct-To-Consumer Genetic Tests
FDA sent letters to five genetic testing firms requesting pre-market submissions for the companies' already-marketed services, citing the need to prove that direct-to-consumer genetic assays are analytically and clinically accurate